Cell & Gene Therapy Financing Solutions 2023 Review


The increasing number and high prices of orphan drugs have triggered concern among patients, payers, and policymakers about the affordability of new drugs approved using the incentives set by the Orphan Drug Act (ODA) of 1983.

The industry is seeking answers to the challenge of financing or payment for cell and gene therapies, with no exact answer to this point in time.

AMI’s report, Cell & Gene Therapy Financing Solutions 2023 Review, provides background on gene therapy, including FDA approved products, financing challenges and solutions, outcome-based contracting and FDA approved products pricing, revenue patient population, and market access.

The report also identifies and provides profiles on the companies offering financing solutions in the market. Each company profile includes background, key decision-makers, solutions, and recent activities.

The report is available for $249 for a single-user license. Department and Corporate Licenses are available, please click here.